Decision Resources Group Release: Over the Next Decade, the Malignant Melanoma Drug Market Will Increase More Than Seven-Fold to $1.5 Billion in 2020

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the malignant melanoma drug market will increase more than seven-fold over the next decade, growing from $210 million in 2010 to $1.5 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although this space had been constrained by a dearth of novel therapies in recent years, robust market growth will be driven by highly anticipated drug approvals—most notably Bristol-Myers Squibb’s Yervoy and Roche/Genentech/Chugai/Daiichi Sankyo’s Zelboraf—which have created significant changes in the treatment of malignant melanoma.